Bio-Rad Laboratories, Inc. BIO
386.48 USD -1.83 (-0.47%)
At closeNov 10, 2026, 4:03 PM EST
386.48 0.00 0.00%
After hours · Nov 10, 4:03 PM ET
381.77 Day range 390.44
241.71 52-week range 390.34
- YTD
- +27.56%
- 1 year
- +25.73%
News
seekingalpha.com Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript Bio-Rad Laboratories, Inc. ( BIO ) 2026 UBS Global Healthcare Conference November 10, 2026 8:00 AM EST Company Participants Roop Lakkaraju - Executive VP & CFO Conference Call Participants Douglas…
globenewswire.com Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S. Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Al
zacks.com Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $390 to $440.
globenewswire.com Medicus Pharma to Present at BIO-Europe 2026 Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight…
marketbeat.com What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset…
seekingalpha.com Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
zacks.com Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.26 per share a year ago.
benzinga.com Bio-Rad Laboratories Q3 2026 Earnings Call Transcript Bio-Rad Laboratories (NYSE:BIO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B vs $2.588B Est Bio-Rad Laboratories (NYSE:BIO) affirms FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.588 billion estimate.
benzinga.com Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $2.23 by 18.83 percent. This is a 17.26 percent increase over earnings of…
businesswire.com Bio-Rad Reports Third-Quarter 2026 Financial Results HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for…
prnewswire.com BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September…
globenewswire.com Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal Cipher, a Prosegur Company, and BIO-key (BKYI) Announce Technology Integration to Expand Identity Security Offering Internationally, Starting in Portugal.
businesswire.com Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief…
globenewswire.com BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem RIYADH, Saudi Arabia and HOLMDEL, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), a global provider of Identity and Access Management (IAM) and biometric…
seekingalpha.com Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds…
seekingalpha.com Ariel Fund Q3 2026 Leaders And Laggards ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology…
globenewswire.com BIO-key Secures Another Middle East Government Contract for its Passwordless, Biometric, Identity and Access Management Solutions BIO-key (BKYI) secured another Middle East government contract (new customer) for its passwordless, biometric, identity & access management (IAM) solutions
gurufocus.com Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overvalued -- GF Score: 73/100 On October 16, 2026, Bio-Rad Laboratories Inc (BIO) shares fell by 3.0%, bringing the current price to $353.70. The stock has experienced a 52-week range of $23
businesswire.com Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026 HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for…
globenewswire.com BIO-key Names Cybersecurity Veteran Stephen Morrow President of PortalGuard to Drive Accelerated Adoption of its Innovative IAM Solution HOLMDEL, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring…
globenewswire.com BIO-key Adds New Middle East Government Security Agency Customer, Expanding Regional Footprint BIO-key (BKYI) Adds New Middle East Government Security Agency, Expands Regional Footprint, Supports National Digital Transformation & Cybersecurity goals.
globenewswire.com Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
benzinga.com Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330 Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.- benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330 Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
benzinga.com Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of…
benzinga.com Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.
benzinga.com Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and the 10-year yield hovers near 4.6% on stalled US-Iran talks.
benzinga.com Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.- benzinga.com 'Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad' - WSJ https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-bio-rad-c99b23fa
benzinga.com RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
benzinga.com Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
benzinga.com Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - benzinga.com Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300 Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
benzinga.com Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5…
benzinga.com Earnings Summary: Bio-Rad Laboratories Q4 
benzinga.com Bio-Rad Laboratories Q4 Adj. EPS $2.51 Misses $2.70 Estimate, Sales $693.200M Beat $688.758M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the analyst consensus estimate of $2.70 by 7.04 percent. This is a 13.45 percent decrease over earnings of…- benzinga.com Earnings Scheduled For February 12, 2026
benzinga.com Qiagen Explores Possible Sale After New Buyer Talks: Report Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.- benzinga.com Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375 Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.